Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.
1 report, 1 independent
Updated Jul 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Ghana
country in West Africa
-
Swissmedic
licensing and inspection authority for remedies in Switzerland with headquarters in Bern
Nothing else this week.
Related events
- Novartis is offering potential support to the national health fund in Ghana, which provides equipment and support to the Komfo Anokye Teaching Hospital.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.
- Novartis is shifting its R&D focus to India, moving operations outside of Switzerland.
- Novartis is headquartered in Basel, Switzerland.